AIM: We report the clinical outcome for a series of ten patients with fibrolamellar hepatocellular treated with resection followed by close surveillance and aggressive management of relapse. METHODS: The case notes for all patients treated at this institution since 1982 were reviewed and details of initial stage and management were extracted along with investigations and treatment of relapse. Time to relapse, overall survival and post-relapse survival were analysed. RESULTS: Relapse occurred in all ten cases at a median of 2.2 (95% CI 0.9-2.7) years but, with a combination of re-resection, systemic chemotherapy and radiotherapy, the overall median survival was 9.3 (95% CI 3.0-18.5) years. One patient was disease free eight years after two resections for recurrent disease. Two of nine patients had a partial response to cisplatin and fluorouracil while three had stable disease. FDG-PET was positive for recurrence in three of four cases of relapse, and in one case detected recurrence in advance of CT. CONCLUSION: The early detection of relapse combined with multimodality therapy results in prolonged survival. Further improvements in systemic therapy are required to improve the prognosis in this disease.
AIM: We report the clinical outcome for a series of ten patients with fibrolamellar hepatocellular treated with resection followed by close surveillance and aggressive management of relapse. METHODS: The case notes for all patients treated at this institution since 1982 were reviewed and details of initial stage and management were extracted along with investigations and treatment of relapse. Time to relapse, overall survival and post-relapse survival were analysed. RESULTS: Relapse occurred in all ten cases at a median of 2.2 (95% CI 0.9-2.7) years but, with a combination of re-resection, systemic chemotherapy and radiotherapy, the overall median survival was 9.3 (95% CI 3.0-18.5) years. One patient was disease free eight years after two resections for recurrent disease. Two of nine patients had a partial response to cisplatin and fluorouracil while three had stable disease. FDG-PET was positive for recurrence in three of four cases of relapse, and in one case detected recurrence in advance of CT. CONCLUSION: The early detection of relapse combined with multimodality therapy results in prolonged survival. Further improvements in systemic therapy are required to improve the prognosis in this disease.
Authors: Celina S Ang; Richard K Do; Ali Shamseddine; Eileen M O'Reilly; Ali Haydar; Ashwaq Al-Olayan; Walid Faraj; Fouad Boulos; Mohamed Naghy; Dorothy Makanjoula; Hassan Farran; Hassan Sibai; David Wehbe; David P Kelsen; Ghassan K Abou-Alfa Journal: Gastrointest Cancer Res Date: 2013-01
Authors: Skye C Mayo; Michael N Mavros; Hari Nathan; David Cosgrove; Joseph M Herman; Ihab Kamel; Robert A Anders; Timothy M Pawlik Journal: J Am Coll Surg Date: 2013-10-24 Impact factor: 6.113
Authors: Timothy A Dinh; Ramja Sritharan; F Donelson Smith; Adam B Francisco; Rosanna K Ma; Rodica P Bunaciu; Matt Kanke; Charles G Danko; Andrew P Massa; John D Scott; Praveen Sethupathy Journal: Cell Rep Date: 2020-04-14 Impact factor: 9.423
Authors: Suguru Yamashita; Jean-Nicolas Vauthey; Ahmed O Kaseb; Thomas A Aloia; Claudius Conrad; Manal M Hassan; Guillaume Passot; Kanwal P Raghav; Mohamed A Shama; Yun Shin Chun Journal: J Gastrointest Surg Date: 2016-07-25 Impact factor: 3.452
Authors: Celina S Ang; R Katie Kelley; Michael A Choti; David P Cosgrove; Joanne F Chou; David Klimstra; Michael S Torbenson; Linda Ferrell; Timothy M Pawlik; Yuman Fong; Eileen M O'Reilly; Jennifer Ma; Joseph McGuire; Gandhi P Vallarapu; Ann Griffin; Francesco Stipa; Marinela Capanu; Ronald P Dematteo; Alan P Venook; Ghassan K Abou-Alfa Journal: Gastrointest Cancer Res Date: 2013-01